Erbitux slightly boosts survival in cancer study
June 1, 2008 By MARILYNN MARCHIONE, AP Medical Writer(AP) -- Adding the novel cancer drug Erbitux to standard chemotherapy helped advanced lung cancer patients live just a month longer than chemo alone, a study found.
Content from The Associated Press expires 15 days after original publication date. For more information about The Associated Press, please visit www.ap.org .
Similar stories from PHYSorg:
Adding cetuximab to chemotherapy reduces advanced lung cancer death risk by 13 percent
Sep 22, 2009 |
not rated yet |
0
Novel 4-drug combination proves safe for lung cancer treatment
Nov 13, 2008 |
5 / 5 (1) |
1
New York doctors testing heated chemo for rare cancer
Mar 05, 2009 |
not rated yet |
1
Surgery remans an option for advanced lung cancer
Jul 27, 2009 |
not rated yet |
1
Study shows drug combination improves outcome for advanced non-small cell lung cancer
May 31, 2009 |
5 / 5 (1) |
0


